A new patent application for using VAR2CSA in combination with novel linkers and toxins for treating solid tumors has been issued in Great Britain, Germany, France, Belgium, Ireland and Switzerland. This new approval adds to the rapidly growing VAR2 Pharma patent portfolio on novel cancer treatment technologies. .
in this publication out today in Nature Communications, VAR2 Pharma co-authors describe how oncofetal chondroitin sulfate is regulated in prostate cancer. The study reports that oncofetal CS is regulated (repressed) by the androgen receptor (AR). When prostate cancer progresses into aggressive AR-independent disease states, these tumors up-regulate oncofetal CS in the tumor via an enzyme […]
Our website only uses strictly necessary cookies. Please consult our Privacy Policy for additional information on how we process your data.